| pubmed-article:12010224 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12010224 | lifeskim:mentions | umls-concept:C0035648 | lld:lifeskim |
| pubmed-article:12010224 | lifeskim:mentions | umls-concept:C0022650 | lld:lifeskim |
| pubmed-article:12010224 | lifeskim:mentions | umls-concept:C0021390 | lld:lifeskim |
| pubmed-article:12010224 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:12010224 | pubmed:dateCreated | 2002-5-15 | lld:pubmed |
| pubmed-article:12010224 | pubmed:abstractText | To correlate renal calculi and other clinical factors with urinary biochemical analytes in patients with inflammatory bowel disease, and to investigate the relative importance of hyperoxaluria (associated with fat malabsorption) or reduced stone inhibitors in the development of calculi in these patients. | lld:pubmed |
| pubmed-article:12010224 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12010224 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12010224 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12010224 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:12010224 | pubmed:issn | 1464-4096 | lld:pubmed |
| pubmed-article:12010224 | pubmed:author | pubmed-author:CampbellSS | lld:pubmed |
| pubmed-article:12010224 | pubmed:author | pubmed-author:DanesiAA | lld:pubmed |
| pubmed-article:12010224 | pubmed:author | pubmed-author:GillandersII | lld:pubmed |
| pubmed-article:12010224 | pubmed:author | pubmed-author:RoltonHH | lld:pubmed |
| pubmed-article:12010224 | pubmed:author | pubmed-author:McConnellNN | lld:pubmed |
| pubmed-article:12010224 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12010224 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:12010224 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12010224 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12010224 | pubmed:pagination | 835-41 | lld:pubmed |
| pubmed-article:12010224 | pubmed:dateRevised | 2006-7-18 | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:meshHeading | pubmed-meshheading:12010224... | lld:pubmed |
| pubmed-article:12010224 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12010224 | pubmed:articleTitle | Risk factors for developing renal stones in inflammatory bowel disease. | lld:pubmed |
| pubmed-article:12010224 | pubmed:affiliation | Biochemistry Department and Gastroenterology Unit, Stobhill Hospital, Glasgow, UK. niel.mcconnell@northglasgow.scot.nhs.uk | lld:pubmed |
| pubmed-article:12010224 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12010224 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12010224 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
